Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
conjugated estrogens/progestin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| conjugated estrogens/progestin (MPA) | DRUG | - |
Inclusion Criteria: * Healthy, postmenopausal women ages 35 to 70 years, inclusive. * Naturally postmenopausal women must not have had a menstrual period for at least six months, but less than 12 months, as confirmed by a blood test; or for at least 12 months with no blood hormone test confirmation...
Conjugated estrogens/progestin is used for estrogen replacement therapy. It is a small molecule being developed by Pfizer, Inc. (PFE) for this endocrine condition. The drug is currently in Phase 1 clinical development as an investigational therapy.
Pfizer, Inc. (PFE) is the developer of conjugated estrogens/progestin. The company is conducting clinical trials to evaluate the drug for estrogen replacement therapy. The drug is currently in Phase 1 development.
Conjugated estrogens/progestin is in Phase 1 clinical development. It is an investigational drug being studied for estrogen replacement therapy. The drug has completed one Phase 1 trial and is not yet approved by regulatory authorities.
Conjugated estrogens/progestin has one completed clinical trial, NCT00401219, titled "Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation." This Phase 1 study enrolled female participants aged 35 years and older.
Conjugated estrogens/progestin is being studied in a trial that compares new formulations to a reference formulation of Premarin/MPA (PREMPRO). The trial NCT00401219 evaluates the bioavailability of three new formulations against the reference product.